News & events

News & events
<picture><source type="image/webp" srcSet="/static/bd6d2c42e99d69343f6fd727c3137fdd/18e05/Image.webp 740w,/static/bd6d2c42e99d69343f6fd727c3137fdd/81bef/Image.webp 1480w,/static/bd6d2c42e99d69343f6fd727c3137fdd/2d0b8/Image.webp 2960w" sizes="(min-width: 2960px) 2960px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2960px) 2960px, 100vw" decoding="async" loading="lazy" src="/static/bd6d2c42e99d69343f6fd727c3137fdd/c9eb6/Image.jpg" srcSet="/static/bd6d2c42e99d69343f6fd727c3137fdd/bbd3f/Image.jpg 740w,/static/bd6d2c42e99d69343f6fd727c3137fdd/087e6/Image.jpg 1480w,/static/bd6d2c42e99d69343f6fd727c3137fdd/c9eb6/Image.jpg 2960w" alt="&lt;p&gt;Image of a middle aged man dressed in a blazer, clapping his hands while smiling.&lt;/p&gt;
"/></picture>

News
1 September 2022Latest
Mendus to participate in upcoming conferences in September
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on improving survival outcomes for cancer patients with tumor recurrence through cell-based immunotherapies, today announced its...
Learn more
26 August 2022
Mendus AB (publ) interim report April – June 2022
Progress made throughout the second quarter puts the company in a strong position to deliver meaningful clinical progress in the second half of 2022, with updated survival data from the ADVANCE II...
Learn more
26 August 2022
Mendus announces financing commitments totaling up to SEK 250 million with Van Herk Investments and Negma Group
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company addressing tumor recurrence through cell-based immunotherapies, today announces that it has entered into a binding agreement for a...
Learn more
14 July 2022
Mendus Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition
Intratumoral injection of allogeneic pro-inflammatory dendritic cells (“ilixadencel”) substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in an established...
Learn more
23 June 2022
Immunicum Announces Corporate Rebranding and Name Change to Mendus AB
Rebranding reflects advancing pipeline in next generation cancer immunotherapies, upcoming manufacturing expansion, and long-term corporate aspirations. The Company’s stock to continue trading under...
Learn more
9 June 2022
Immunicum Received FDA Orphan Drug Designation for Ilixadencel as Treatment of Gastrointestinal Stromal Tumors (GIST)
Immunicum announced that it has been granted an Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for ilixadencel in the treatment of Gastrointestinal Stromal Tumors (GIST).
Learn more
1 June 2022
Immunicum to Participate in Upcoming Conferences
Immunicum today announced its participation in the following upcoming conferences:...
Learn more

Events
28 September 2022
Upcoming
Next Frontiers in Cancer VaccinesMendus CEO Erik Manting will present on September 28th, 2022 at 3:10 pm CET at the event organized by HollandBIO and the Oncode Institute.
Learn more
September 2022Previous
Sachs 22nd Annual Biotech in Europe Forum
The 22nd Annual Biotech in Europe Forum will take place in-person on September 21-22, 2022, at the Mövenpick Hotel in Basel, Switzerland. Mendus' CEO Erik Manting will present on September 21, 2022.
Learn more
September 2022Previous
Pareto Securities’ 13th Annual Healthcare Conference
On 7-8 September 2022, Pareto Securities will host its 13th Annual Healthcare Conference. Mendus' CEO Erik Manting will present at the conference.
Learn more
September 2022Previous
LSX Nordic Congress 2022
The LSX Nordic Congress will take place on 6-7 September, 2022, at the AC Hotel Bella Sky in Copenhagen, Denmark. Mendus' CEO Erik Manting will present on June 6, 2022.
Learn more

.FullWidthImage-module--bg-image-mobile--1fPGr.FullWidthImage-module--hide-in-mobile--XC8T7.gbi-1002417752-o9YHHtSXjNpJZHvwfVc7Ao:before { opacity: 1; background-image: url('/static/755e562542c233156a7bec1f19e2a86b/afb86/new-events-mobile.png'); }

InvestorsAt Mendus, we share a strong commitment to improve the lives of people with cancer.
Investors

News

Mendus to participate in upcoming conferences in September

Mendus AB (publ) interim report April – June 2022

Mendus announces financing commitments totaling up to SEK 250 million with Van Herk Investments and Negma Group

Mendus Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition

Immunicum Announces Corporate Rebranding and Name Change to Mendus AB

Immunicum Received FDA Orphan Drug Designation for Ilixadencel as Treatment of Gastrointestinal Stromal Tumors (GIST)

Immunicum to Participate in Upcoming Conferences

Events

Next Frontiers in Cancer Vaccines

Sachs 22nd Annual Biotech in Europe Forum

Pareto Securities’ 13th Annual Healthcare Conference

LSX Nordic Congress 2022

Investors

Keep up to date